People · Operator
Named in public records as an officer, director or promoter · active 2020–2020 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Item 9 Labs Corp. | — | Pharmaceuticals | Series B | $33.4M | $356.4M | 2020 |
Christopher L Wolven at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Christopher L Wolven on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Ronald L. Miller, Jr. | 1 | 5 |
| Ronald Miller | 1 | 4 |
| JEFFREY RASSAS | 1 | 3 |
| DANIEL J. COHEN | 1 | 1 |
| RONALD J. MILLER | 1 | 1 |
| JESSICA SMITH | 1 | 1 |
| Robert Mikkelsen | 1 | 1 |
| Andrew Bowden | 1 | 1 |
| Michael L Keskey | 1 | 1 |
| Jeffrey L Rassas | 1 | 1 |
| Douglas L Bowden | 1 | 1 |
| Bryce L Skalla | 1 | 1 |
| Sara Gullickson | 1 | 1 |
| Bryce Skalla | 1 | 1 |
| Robert Mikkelson | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.